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OBJECTIVES The aim of our study was to assess whether left atrial appendage (LAA) ligation in patients
undergoing mitral valve replacement is associated with the risk of future embolisms.
BACKGROUND Previous studies show that the LAA plays an important role in the development of
intracardiac thrombus. According to this decisive role, LAA surgical closure in patients
undergoing cardiac surgery may be an attractive choice for reducing stroke.
METHODS We retrospectively studied 205 patients with previous mitral valve replacement and referred
for echocardiography study. Patients were excluded if other causes of systemic embolism were
found. The main outcome measure was the occurrence of an embolic event.
RESULTS Ligation of LAA was performed in 58 patients. However, an incomplete ligation was verified
in six patients. During a median time from valve replacement to echocardiography study of
69.4 months (1 to 329), 27 patients had an embolism. Multivariate analysis identified the
absence of LAA ligation (odds ratio [OR] 6.7 [95% confidence interval {CI} 1.5 to 31.0]; p
0.02) and the presence of left atrial thrombus as the only independent predictors of occurrence
of an embolic event. Moreover, when the identification of an incomplete LAA ligation was
considered together with the absence of LAA ligation, risk of embolism increased up to
11.9  (OR 11.9 [95% CI 1.5 to 93.6]; p  0.02).
CONCLUSIONS Our study shows that LAA ligation during surgery of mitral valve replacement, performed in
a high-risk population, is consistent with a reduction of the risk of late embolism and supports
this technique if a mitral valve replacement is indicated. (J Am Coll Cardiol 2003;42:
1253–8) © 2003 by the American College of Cardiology Foundation
The left atrial appendage (LAA) plays a fundamental role in
the formation of atrial thrombus in patients with atrial
fibrillation (AF). In patients with nonrheumatic AF, LAA
is the origin of at least 90% of all left atrial (LA) clots (1–3),
and the resulting systemic emboli cause approximately 25%
of all strokes (4,5). Moreover, in patients in sinus rhythm in
whom an LA thrombus was diagnosed with standard
echocardiography, LAA location was involved in 95% of the
cases (6).
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Transesophageal echocardiography (TEE) is the gold-
standard diagnostic method for the detection of thrombus
in the LAA. The size of the LAA, the reduction of LAA
flow velocities (7–11), and the detection of spontaneous
echo contrast in either the LA or the LAA have been
suggested as markers of increased embolism risk (12–16).
According to the decisive role of LAA in thrombus
formation, LAA surgical ligation in patients undergoing
cardiac surgery may be an attractive choice for reducing
stroke risk (17,18). In addition, LAA closure can be now
achieved through different approaches such as thoracoscopic
LAA ligation (19) and, more recently, percutaneous LAA
occlusion (20,21).
However, to our knowledge, no prior study in a large and
homogeneous population has analyzed the role of LAA
ligation in the prevention of strokes or systemic embolic
phenomena after a surgical intervention. As a result, inter-
mittent and unsystematic LAA ligation is performed by
surgeons worldwide. We hypothesized that LAA ligation
would be associated with lower stroke risk and designed a
retrospective study of patients undergoing mitral valve
replacement. The aim of our study was to assess whether
LAA ligation is associated with the risk of future embolism.
METHODS
Study population. A total of 242 patients with prior mitral
valve replacement, referred to our echocardiography labora-
tory from February 1996 to October 2001, were included for
the study. Patients were referred for echocardiography by
their physician and were both studied with transthoracic
and TEE. The indications for referral were 82 patients for
quantification of mitral valve regurgitation, 48 patients that
were investigated for suspected mitral valve endocarditis, 42
patients for investigation of an embolic source, 30 patients
for evaluation of right or left ventricular function, 25
patients for further evaluation of a detected increase in
mitral prosthesis diastolic gradient, and 15 patients were
studied for miscellaneous indications.
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Patients were excluded if other potential causes of sys-
temic embolism were found in the echocardiographic study:
thrombotic occlusion of the prosthetic valve (n  11),
confirmed endocarditis (n  9), aortic dissection (n  1),
and if an extracardiac source were found to be the origin of
the embolism (n  16).
The final study group consisted of 205 patients (130
women) with a mean age of 62.4 years. The reason for the
mitral valve replacement was rheumatic valve disease in 170
patients, mitral valve endocarditis in 10 patients, severe
ischemic regurgitation in 6 patients, and mitral valve pro-
lapse in 19 patients. All patients with mechanical prostheses
underwent anticoagulation treatment with acenocumarin,
and those with biological valves were either anticoagulated
or received antiplatelet therapy.
Study flow. Retrospective analysis of the patients after
mitral valve replacement was supported by a review of
patient records. Main outcome measure was the occurrence
of an embolic event, considering only those appearing after
48 h of the surgery. An embolic event was defined by the
presence of clinical signs and the verification with at least
one of the following diagnostic tools: computed tomography
(neurological events) or angiography and/or surgery (pe-
ripheral artery events).
The clinical diagnosis of an embolic transient ischemic
attack, or stroke, was made by a neurologist. Those patients
with deficits in the posterior cerebral circulation territory or
with lacunar strokes were excluded.
Echocardiography. Conventional transthoracic echocardi-
ography was performed with either a Sonos 5500 (Philips
Technologies, Andover, Massachusetts) or an Acuson Se-
quoia 256 (Siemens Technologies, Mountain View, Cali-
fornia) using a phased array transducer. Transesophageal
echocardiography was performed using an omniplane probe
in 182 patients and with a biplane TEE probe in the
remaining patients.
Cardiac structures and the aorta were visualized from
multiple esophageal and transgastric views. Prosthetic mitral
valve area was estimated using the pressure half-time
method (22). Mitral regurgitation jet was visualized using
color Doppler flow and graded to determine the severity of
mitral regurgitation by a previously validated method (23).
Maximal LAA areas were measured by tracing a line from
the top of the upper pulmonary vein limbus along the entire
endocardial LAA border (8).
The LA and LAA were closely inspected for the presence
of thrombi and spontaneous echo contrast. The severity of
LAA spontaneous echo contrast (LASEC) was graded from
0 to 4 following the classification of Fatkin et al. (24).
Surgical ligation of the LAA was clearly identified by the
lack of any anatomical structure between the mitral valve
base and the upper left pulmonary artery (25) (Fig. 1A and
1B). Incomplete ligation was diagnosed by color Doppler
flow, demonstrating a jet traversing the separation between
LAA and the LA body (25) (Fig. 2).
Statistical analysis. Data are expressed as mean  SD.
Proportions were compared with the chi-square test. If any
of the cells from a 2  2 table had an expected count below
5, then a Fisher exact test was applied. Quantitative vari-
ables were normally distributed and compared with a
Student t test. The independent contribution of the poten-
tial factors involved in embolism was analyzed with a
logistic regression. In the multiple regression analysis, the
dependent variable was the occurrence of an embolic event,
and the independent variables were those that showed, on
univariate analysis, a significant correlation with the occur-
rence of an embolic event as well as variables that showed a
trend (p  0.25) and those with well-known clinical
relevance. Differences were considered to be statistically
significant if the null hypothesis could be rejected with
Abbreviations and Acronyms
AF  atrial fibrillation
LA  left atrial/atrium
LAA  left atrial appendage
LASEC  left atrial appendage spontaneous echo
contrast
TEE  transesophageal echocardiography
Figure 1. (A) Transesophageal echocardiogram in a patient with Saint Jude medical prosthesis in mitral position and without ligation of the left atrial
appendage (LAA) (arrows). (B) Postoperative transesophageal echocardiographic study showing the absence of the LAA with complete obliteration of the
cavity (arrows). LA  left atrium; P  prosthesis.
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95% confidence interval. Two different multivariate anal-
yses were carried out. The first one was an intention-to-treat
analysis including as independent variable the surgical clo-
sure of the LAA, and, in the second analysis, only the
effective closure of LAA assessed by TEE was considered.
The SPSS 10.0 statistical software package (SPSS Inc.,
Chicago, Illinois) was used for all calculations.
RESULTS
A total of 205 patients was included in the study. Only 29
patients (14.1%) were in sinus rhythm. Mechanical prostheses
were placed in 187 patients (71 Carbomedics [Carbomedics,
Inc., Austin, Texas], 50 SJ Medical [St. Jude Medical, Inc., St.
Paul, Minnesota], 27 Bjo¨rk-Shiley [Shiley Laboratories, Inc.,
Santa Ana, California], 14 Medtronic Hall [Medtronic, Inc.,
Minneapolis, Minnesota], and 26 miscellanea). All other
patients were treated with biological prostheses. Mild valve
regurgitation was found in 29 patients (14.1%), moderate in 24
(11.7%), and severe in 22 patients (10.7%).
Complete ligation of the LAA was achieved in 52
patients and incomplete in six patients (10.3% of patients
with LAA ligation). Remaining patients had no LAA
ligation performed during surgery.
The mean time from valve replacement until the echocar-
diographic study was performed was 69.4  67 months (1 to
329). During this time, peripheral arterial embolization was
identified in 27 patients. In 24 patients, the embolic event
occurred within one week before performing the TEE, and in
three cases within two weeks. Among patients with embolisms,
19 suffered an ischemic stroke, five peripheral embolism, and
three patients a transient ischemic attack. Of these, three
demonstrated an LAA thrombus (including one patient with
incomplete LAA ligation), and one patient had an LA throm-
bus. In addition, LA thrombi were observed in another six
patients without embolism (located in the LAA in two
patients, in the LA main cavity in two patients, and in both
locations in another two patients).
Figure 2. Transesophageal echocardiographic study. Transverse view of an incompletely ligated left atrial appendage (LAA). Color-coded flow transverses
the communication between the LAA and the left atrium (LA) body (arrow).
Table 1. Characteristics of Patients With LAA Ligation at Surgery Versus No LAA
LAA Ligation
(n  58)
No LAA Ligation
(n  147) p Value
Age (yrs) 63  12 62  10 0.8
Female gender 44 (75.9%) 89 (58.5%) 0.02
LA size (cm) 60  12 57  11 0.07
LA or LAA thrombus 3 (5.2%) 7 (4.8%) 0.9*
Mean LVEF (%) 56  10 57  13 0.7
Moderate-severe LVEF depression 8 (13.8%) 25 (17%) 0.6
Severe mitral prosthetic regurgitation 4 (6.9%) 18 (12.2%) 0.3
Sinus rhythm 5 (8.6%) 24 (16.3%) 0.2
Mean time from MVR to TEE (months) 83  73 64  63 0.07
Recent embolism 2 (3.4%) 25 (17%) 0.01
*Fisher test was performed instead of chi-squared test. Data are expressed as mean  SD or number (percentage).
LA left atrium; LAA left atrial appendage; LVEF left ventricular ejection fraction; MVRmitral valve replacement;
TEE  transesophageal echocardiography.
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Table 1 shows the characteristics of patients according to
LAA ligation. Left atrial appendage ligation was performed
more frequently in women (75.9% of the patients with LAA
ligation compared with only 58.5% of the patients with no
ligation; p  0.02). The occurrence of a systemic embolism
was significantly more frequent in patients without LAA
ligation compared with patients with LAA ligation (17% vs.
3.4% respectively; p  0.01).) Only two of the 27 embolic
events occurred in patients with LAA ligation. In addition
to the absence of LAA ligation, the presence of LA or LAA
thrombus (14.8% vs. 3.4%; p  0.03) and LASEC grade 3
or 4 (64% vs. 21.3%; p  0.001) was also more frequent in
patients with an embolic event compared with patients
without systemic embolism (Table 2).
Multivariate analysis identified the absence of LAA
ligation (odds ratio [OR] 6.7 [95% CI 1.5 to 31.0]; p 
0.02) and the TEE finding of an LA or LAA thrombus
(OR 5.8 [95% CI 1.2 to 27.3]; p0.03) as the only
independent predictors of occurrence of an embolic event
after mitral valve replacement surgery (Table 3). Moreover,
if the absence of effective ligation as assessed by echocardi-
ography was included in the model, OR increased up to 11.9
(95% CI 1.5 to 93.6), p  0.02, and the presence of LA or
LAA thrombus also remained independently associated
with the occurrence of an embolic event (Table 3).
If only patients without LAA ligation were included in
the analysis, events were more frequent in patients with
larger LAA size (8.6 1.0 mm vs. 7.7 1.1 mm in patients
with and without embolic events respectively; p  0.001)
and in those with greater LASEC score (64% of patients
with embolic event had a score 3 or 4 compared with 21.3%
of patients without event; p  0.0005). The presence of LA
or LAA thrombus was close to reaching statistical signifi-
cance (12% vs. 3.3% in patients with and without embolic
events respectively; p0.06). After multivariate analysis, the
only independent variable associated with the occurrence of
embolisms in these group of patients was the LASEC score
(OR 3.0 [95% CI 1.5 to 6.0]; p  0.002) (Table 4).
DISCUSSION
LAA ligation during surgical procedures. Several studies
have confirmed that the LAA plays a very important role in
Table 2. Characteristics of Patients With Embolic Events
Versus No Embolic Event
Embolic Event
(n  27)
No Embolic
Event
(n  178) p Value
Age (yrs) 62  12 62  10 0.9
Female gender 18 (66.7%) 112 (62.9%) 0.7
Mean time from MVR
to TEE (months)
73.8  60.9 68.6  68.2 0.7
Mechanical prosthesis 24 (88.9%) 163 (91.6%) 0.6
LA size 55  10 58  12 0.2
LA or LAA thrombus 4 (14.8%) 6 (3.4%) 0.03*
Mean LVEF 59  14 56  12 0.5
Sinus rhythm 4 (14.8%) 25 (14%) 0.9
LAA ligation 2 (7.4%) 56 (31.5%) 0.01
Severe mitral prosthetic
regurgitation
2 (7.4%) 20 (11.2%) 0.7*
LASEC grade 3 or 4 16 (64%) 26 (21.3%)  0.001†
*Fisher test was performed instead of chi-squared test. †In the analysis of this variable,
only patients without LAA ligation were included.
LASEC left atrial appendage spontaneous echo contrast. Other abbreviations as
in Table 1.
Table 3. Factors Independently Associated With Embolic Events
Logistic Regression Procedure Evaluating the Absence of LAA Ligation Performed at Surgery
B OR (95% CI) p Value
Absence of LAA ligation at MVR 1.9 6.7 (1.5–31.0) 0.02
LA or LAA thrombus 1.8 5.8 (1.2–27.3) 0.03
Age (per yr) 0.02 1.0 (0.9–1.1) 0.5
Female gender 0.07 1.1 (0.4–2.8) 0.9
Time from MVR to TEE (per month) 0.01 1.0 (0.9–1.0) 0.2
LVEF 0.01 1.0 (0.9–1.1) 0.7
Mitral regurgitation 0.2 0.8 (0.5–1.3) 0.3
LA size 0.03 1.0 (0.9–1.1) 0.2
Sinus rhythm 0.03 1.0 (0.3–3.5) 0.9
Logistic Regression Procedure Evaluating the Absence of Effective LAA Ligation in TEE
Absence of LAA ligation in TEE 2.5 11.9 (1.5–93.6) 0.02
LA or LAA thrombus 1.6 5.1 (1.1–23.2) 0.04
Age (per yr) 0.02 1.0 (0.9–1.1) 0.5
Female gender 0.09 1.1 (0.4–2.9) 0.9
Time from MVR to TEE (per month) 0.005 1.0 (0.9–1.0) 0.2
LVEF 0.01 1.0 (0.9–1.1) 0.5
Mitral regurgitation 0.3 0.8 (0.5–1.2) 0.3
LA size 0.03 1.0 (0.9–1.1) 0.3
Sinus rhythm 0.07 0.9 (0.3–3.4) 0.9
In both models the same factors were evaluated, excepting absence of LAA ligation (at MVR in the first model or at TEE in
the second model).
CI  confidence interval; OR  odds ratio. Other abbreviations as in Table 1.
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the development of thromboembolic strokes. In patients
with rheumatic and nonrheumatic AF, at least 60% and
90% of LA thrombi, respectively, are located in the LAA
(1–3). Therefore, it is likely that ligation of the LAA would
greatly reduce the risk of stroke.
Since the early rheumatic mitral stenosis surgical proce-
dures (17,18), LAA ligation has been performed attempting
to reduce the risk of embolization. Ligation of the LAA
during mitral valve replacement surgery is still controversial.
Some authors propose that prophylactic appendage removal
should be performed whenever the chest is open as a
method of preventing future strokes (26). Surprisingly, the
benefit of carrying out such a commonly performed proce-
dure is poorly documented in scientific literature, and its use
has been sporadic and governed by intuition alone (3). The
utilization of this technique depends on the methodology
and insight of the different surgical teams despite that it is
a recommended procedure in the ACC guidelines (27).
Orszulak et al. (28) evaluated the risk of stroke in elderly
patients during the early postoperative period after a mitral
valve replacement with a Carpentier-Edwards biological
prosthesis and found a strong correlation between late
stroke in patients having the LAA ligated when patients
underwent mitral valve replacement and coronary bypass
grafts. However, in the group of patients with isolated
mitral valve replacement and in the overall group, the only
independent variable associated with a greater risk of late
stroke was an advanced heart class.
Juratli et al. (29) analyzed the use of LAA ligation during
mitral valve surgery (50% underwent mitral valve repair and
23% received a mechanical prosthesis) as an alternative to
anticoagulant treatment with warfarin. Left atrial append-
age ligation did not provide an adequate protection from
thromboembolic events in the absence of effective antico-
agulation treatment with warfarin. Our study population,
unlike the patient population studied by Juratli et al. (29) and
Orszulak et al. (28), had received acenocumarin treatment in
82% of cases, and in all the cases when a patient received a
mechanical prosthesis. In addition, the majority of subjects
were diagnosed with chronic rheumatic mitral valve disease,
and a greater enlargement of the LA was observed.
LAA incomplete ligation. A special group of patients are
those with incomplete surgical ligation of the LAA. Katz et
al. (25) recently reported that 36% of patients had incom-
plete ligation of the LAA after a mitral valve surgery, and
22% of them suffered an embolic event. In our study the
frequency of incomplete ligation of the LAA was only
10.3%, of which only one case suffered an embolic event.
There is no doubt about the influence of the surgical
technique on these findings. In the series of Katz et al. (25),
a running suture was performed, whereas our surgeons
carried out a double suture (a purse string suture as well as
a running suture). This double suture probably provides a
more stable LAA ligation. The high incidence of incom-
plete ligation of the LAA should be noted, and further
investigation is required to establish if this can result in an
increased incidence of postoperative embolic events.
Selection of patients for LAA ligation. The physiological
role of the LAA is minimal, and consequently, its removal
has been advocated over the years to reduce stroke risk. At
this point, an interesting application of TEE may be to
identify patients for LAA ligation; TEE can define a
high-risk population if a low or absent LAA flow velocity
profile or the presence of LASEC is identified (8). It could
be argued that ligation of the LAA is unnecessary in those
high-risk patients because they will receive anticoagulation
therapy for decades. However, it is well known that, despite
clear guidelines, warfarin is either not used or used improp-
erly on a large scale (30–32). In addition, warfarin levels are
affected by a large number of dietary and drug factors (3).
Thus, it is clear that variations in the therapeutic effective-
ness of long-term treatments are almost the norm, and it is
in these changes where the appearance of embolic events can
take place. Thus, it would appear sensible to eliminate the
fundamental origin of the embolic events.
Our study shows for the first time that LAA ligation
during surgery of mitral valve replacement, performed in a
high-risk population, is consistent with a reduction of the
risk of late embolism (6.7-fold reduction in embolic risk).
Moreover, if a complete ligation is achieved and confirmed
with TEE, a further reduction in embolism risk is observed
(11.9-fold reduction in embolic risk). In addition, the TEE
identification of LAA or LA thrombus, higher LA size, or
higher degrees of LASEC is associated with a higher risk of
late embolisms. These findings represent a strong negative
association between an embolic event and ligation of the
LAA during surgical intervention, thus providing clear
evidence for the benefit of ligation of the LAA during
surgical procedure as a method of preventing a postoperative
embolic event. Because we studied mainly patients with
rheumatic valvular disease, our results may be applicable
only to this population. However, an ongoing randomized
trial of LAA occlusion during routine coronary artery bypass
graft surgery (Left Atrial Appendage Occlusion Study
[LAAOS] study) (33) will be able to provide definitive
Table 4. Factors Independently Associated With Embolic
Events Evaluated Only in Patients Without LAA Ligation
Performed at Surgery (n  147)
B OR (95% CI) p Value
LASEC* 1.09 3.0 (1.5–6.0) 0.002
Age (per yr) 0.01 1.0 (0.9–1.17) 0.7
Female gender 0.37 1.5 (0.5–4.4) 0.5
Mechanical mitral
prosthesis
0.004 1.0 (0.9–1.2) 0.9
Mitral regurgitation 0.37 1.4 (0.7–3.0) 0.3
LAA size 0.29 1.3 (0.8–2.2) 0.3
LA size 0.03 1.0 (0.9–1.1) 0.2
Sinus rhythm 0.18 1.2 (0.2–6.9) 0.8
LA or LAA thrombus 1.13 3.1 (0.6–17.6) 0.2
*OR related to each grade of increase of severity. Logistic regression procedure
including the following variables: age, gender, mechanical mitral prosthesis, LA size,
LAA size, sinus rhythm, LA thrombus, mitral prosthetic regurgitation.
Abbreviations as in Tables 1, 2, and 3.
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evidence about LAA ligation in patients without rheumatic
valvular disease.
Study limitations. The study population consisted of pa-
tients referred to the echocardiography laboratory for mitral
valve prosthesis evaluation using TEE. This pretest referral
bias can result in an amplification of the beneficial effect of
LAA ligation if fewer patients who had mitral valve replace-
ment and LAA ligation would be referred for echocardio-
graphic study. Another limitation is the lack of information
about anticoagulation levels in these patients. Although all
patients with a mechanical prosthesis were anticoagulated, it
could be possible that lower international normalized ratio
levels influenced the development of an embolic event.
Despite its evident clinical relevance, there is no reason to think
that patients with LA appendectomy have a different chronic
anticoagulation profile than patients without it. Thus, the
degree of chronic anticoagulation should not be a confounding
factor in this setting.
Our study supports the surgical LAA ligation together
with the mitral valve replacement. It provides new informa-
tion about potential impact of LAA ligation until new data
of a randomized study with blinded event verification are
available (33).
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